表纸
市场调查报告书

再生医疗的全球市场 (~2025年):各产品 (细胞治疗药 (自体、同类)、干细胞治疗药、组织工程产品、基因治疗药)、疾病区分 (创伤护理、肌肉骨骼、癌症、牙科、眼科)、地区

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

出版商 MarketsandMarkets 商品编码 962876
出版日期 内容资讯 英文 160 Pages
订单完成后即时交付
价格
再生医疗的全球市场 (~2025年):各产品 (细胞治疗药 (自体、同类)、干细胞治疗药、组织工程产品、基因治疗药)、疾病区分 (创伤护理、肌肉骨骼、癌症、牙科、眼科)、地区 Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025
出版日期: 2020年09月30日内容资讯: 英文 160 Pages
简介

全球再生医疗的市场规模在预测期间内15.9%的年复合成长率发展,从2020年的85亿美元,2025年179亿美元的规模成长。慢性疾病,遗传性疾病,癌症的盛行率上升,再生医疗研究的投资增加,产品平台的扩大等要素促进该市场成长。同时,基因治疗的R&D的高成本,胚胎干细胞的使用相关道德的疑虑等课题预计妨碍市场进一步成长。

本报告提供全球再生医疗的市场调查,市场定义和概要,新型冠状病毒感染疾病 (COVID-19) 以及其他的市场影响因素分析,市场规模的变化、预测,产品、疾病区分、地区/主要国家等各种区分的明细,竞争环境,主要企业简介等资讯汇整。

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 重要考察

第5章 市场概要

  • 市场动态
    • 促进因素
    • 规定
    • 市场机会
  • COVID-19的影响

第6章 市场分析、预测:各产品

  • 组织工程产品
  • 细胞治疗药
    • 自体细胞治疗药
    • 同种异体细胞治疗药
  • 基因治疗药
  • 前驱细胞、干细胞治疗药

第7章 市场分析、预测:各疾病种类

  • 肌肉骨骼系统障碍
  • 癌症
  • 创伤护理
  • 牙科疾病
  • 眼科疾病
  • 其他

第8章 市场分析、预测:各地区、主要国家

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 其他
  • 亚太地区
    • 日本
    • 中国
    • 澳洲
    • 其他
  • 其他地区

第9章 竞争情形

  • 概要
  • 市场占有率分析:细胞治疗
  • 市场占有率分析:基因治疗
  • 组织工程市场排行榜
  • 竞争模式

第10章 企业评估矩阵、企业简介

  • 企业的评估矩阵:定义、调查手法
  • 企业的评估矩阵:新兴企业
  • 企业简介
    • SMITH & NEPHEW PLC
    • VERICEL CORPORATION
    • INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    • MIMEDX GROUP
    • NOVARTIS AG
    • STRYKER CORPORATION
    • ORGANOGENESIS INC.
    • MEDIPOST CO., LTD.
    • 3M GROUP
    • MISONIX
    • ZIMMER BIOMET
    • MEDTRONIC PLC
    • AMGEN, INC.
    • ALLERGAN
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • ORTHOCELL LTD.
    • TEGO SCIENCE, INC.
    • CORESTEM, INC.
    • ANTEROGEN CO., LTD.
    • BLUEBIRD BIO
    • SPARK THERAPEUTICS
    • KITE PHARMA
    • 亚太地区 BIOTECH
    • SHENZHEN SIBIONO GENETECH CO., LTD.
    • ASPECT BIOSYSTEMS

第11章 附录

目录
Product Code: BT 4419

The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% during the forecast period. Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

"The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period "

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

"Oncology segment accounted for highest CAGR"

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

"Europe: The fastest-growing region regenerative medicine market"

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World - 12%

Lits of companies Profiled in the Report:

  • 3M (US)
  • Allergan plc (Ireland)
  • Amgen, Inc. (US)
  • Aspect Biosystems (Canada)
  • bluebird bio (US)
  • Kite Pharma (US)
  • Integra LifeSciences Holdings Corporation (US)
  • MEDIPOST Co., Ltd. (South Korea)
  • Medtronic plc (Ireland)
  • Anterogen Co., Ltd. (South Korea)
  • MiMedx Group (US)
  • Misonix (US)
  • Novartis AG (Switzerland)
  • Organogenesis Inc. (US)
  • Orthocell Limited (Australia)
  • Corestem, Inc. (South Korea)
  • Spark Therapeutics (US)
  • APAC Biotech (India)
  • Shenzhen Sibiono GeneTech Co., Ltd. (China)
  • Smith & Nephew plc (UK)
  • Stryker Corporation (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Tego Science (South Korea)
  • Vericel Corporation (US)
  • Zimmer Biomet (US)

Research Coverage:

This report provides a detailed picture of the global regenerative medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as product, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and trends.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • FIGURE 1 INCLUSIONS & EXCLUSIONS
    • 1.2.1 MARKETS COVERED
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 REPORT COMPARISON WITH THE MARCH 2019 EDITION
    • 1.6.1 SUMMARY OF CHANGES
    • 1.6.2 LIMITATIONS OF THE CURRENT EDITION

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 4 REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 5 REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 7 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
    • FIGURE 8 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
    • FIGURE 9 REGENERATIVE MEDICINE MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 REGENERATIVE MEDICINE MARKET OVERVIEW
    • FIGURE 10 GROWING INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
  • 4.2 CELL THERAPIES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 11 AUTOLOGOUS CELL THERAPIES TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN THE FORECAST PERIOD
  • 4.3 REGENERATIVE MEDICINE MARKET SHARE, BY APPLICATION, 2020 VS. 2025
    • FIGURE 12 MUSCULOSKELETAL DISORDERS IS THE LARGEST APPLICATION SEGMENT OF THE REGENERATIVE MEDICINE MARKET
  • 4.4 REGENERATIVE MEDICINE MARKET, BY REGION, 2020-2025
    • FIGURE 13 NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 14 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of chronic diseases, genetic disorders, and cancer
    • FIGURE 15 INCIDENCE OF DIABETES, BY REGION, 2015 VS. 2040 (MILLION CASES)
    • TABLE 1 CANCER INCIDENCE AND MORTALITY, BY REGION, 2012-2035
    • TABLE 2 OBESITY-ASSOCIATED DEATH RATE (%), BY COUNTRY, 2017
      • 5.2.1.2 Rising investments in regenerative medicine research
    • TABLE 3 TOTAL FUNDING, BY SOURCE TYPE, 2016-2019 (USD MILLION)
    • TABLE 4 FUNDING FROM CORPORATE PARTNERSHIPS, 2018-2019 (USD MILLION)
    • TABLE 5 FUNDRAISING THROUGH PUBLIC OFFERINGS (IPO & FOLLOW-ONS), 2018-2019 (USD MILLION)
    • TABLE 6 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY THE NIH UNDER THE 21ST CENTURY CURES ACT, 2017-2019 (USD BILLION)
    • TABLE 7 CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE FUNDING FOR REGENERATIVE MEDICINE RESEARCH (2017)
      • 5.2.1.3 Growing pipeline of regenerative medicine products
    • TABLE 8 NUMBER OF COMPANIES OPERATING IN THE REGENERATIVE MEDICINE MARKET, BY REGION, 2016-2018
    • TABLE 9 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET, BY CLINICAL PHASE, 2018 VS. 2019
    • TABLE 10 NUMBER OF M&A TRANSACTIONS, 2016-2019 (USD MILLION)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Ethical concerns related to the use of embryonic stem cells in research & development
      • 5.2.2.2 High cost of cell and gene therapies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Implementation of the 21st Century Cures Act
      • 5.2.3.2 Rising demand for organ transplantations
  • 5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE REGENERATIVE MEDICINE MARKET

6 REGENERATIVE MEDICINE MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 11 FUNDING FOR REGENERATIVE MEDICINE PRODUCTS, 2019 (USD BILLION)
    • TABLE 12 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET, 2018 VS. 2019
    • TABLE 13 NEW PRODUCT APPROVALS IN THE REGENERATIVE MEDICINE MARKET, 2018-2020
    • TABLE 14 REGENERATIVE MEDICINE MARKET: PRODUCT PIPELINE (2019)
    • TABLE 15 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • 6.2 TISSUE-ENGINEERED PRODUCTS
    • 6.2.1 RISING PREVALENCE OF CHRONIC WOUNDS TO DRIVE THE MARKET GROWTH
    • TABLE 16 EXAMPLES OF COMMERCIALIZED TISSUE-ENGINEERED PRODUCTS
    • TABLE 17 TISSUE-ENGINEERED PRODUCTS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 18 NORTH AMERICA: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 19 EUROPE: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 20 APAC: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 6.3 CELL THERAPIES
    • TABLE 21 COMMERCIALIZED CELL THERAPIES AVAILABLE IN THE MARKET
    • TABLE 22 CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 23 CELL THERAPIES MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 24 NORTH AMERICA: CELL THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 25 EUROPE: CELL THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 26 APAC: CELL THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.3.1 AUTOLOGOUS THERAPIES
      • 6.3.1.1 Autologous therapies segment to register the highest growth in the cell therapies market
    • TABLE 27 EXAMPLES OF COMMERCIALIZED AUTOLOGOUS CELL THERAPIES
    • TABLE 28 AUTOLOGOUS THERAPIES MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 29 NORTH AMERICA: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 30 EUROPE: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 31 APAC: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.3.2 ALLOGENEIC THERAPIES
      • 6.3.2.1 Rising incidence of chronic conditions to drive the market growth
    • TABLE 32 EXAMPLES OF COMMERCIALIZED ALLOGENEIC CELL THERAPIES
    • TABLE 33 ALLOGENEIC THERAPIES MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 34 NORTH AMERICA: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 35 EUROPE: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 36 APAC: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 6.4 GENE THERAPIES
    • 6.4.1 GROWING NUMBER OF CANCER CASES TO DRIVE MARKET GROWTH
    • TABLE 37 EXAMPLES OF COMMERCIALIZED GENE THERAPIES
    • TABLE 38 GENE THERAPIES MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 39 NORTH AMERICA: GENE THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 40 EUROPE: GENE THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 41 APAC: GENE THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 6.5 PROGENITOR & STEM CELL THERAPIES
    • 6.5.1 GROWING PRODUCT PIPELINE TO SUPPORT THE GROWTH OF THIS SEGMENT
    • TABLE 42 EXAMPLES OF COMMERCIALIZED PROGENITOR & STEM CELL THERAPIES
    • TABLE 43 PROGENITOR & STEM CELL THERAPIES MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 44 NORTH AMERICA: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 45 EUROPE: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 46 APAC: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

7 REGENERATIVE MEDICINE MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 47 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY APPLICATION, 2018 VS. 2019
    • TABLE 48 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • 7.2 MUSCULOSKELETAL DISORDERS
    • 7.2.1 INCREASING PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
    • TABLE 49 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 50 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 51 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 52 APAC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.3 ONCOLOGY
    • 7.3.1 INCREASING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH
    • TABLE 53 NUMBER OF PATIENTS, BY TYPE OF CANCER, 2012-2030
    • TABLE 54 INDICATIVE LIST OF FEW COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR THE TREATMENT OF CANCER
    • TABLE 55 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 56 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 57 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 58 APAC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.4 WOUND CARE
    • 7.4.1 RISING PREVALENCE OF CHRONIC CONDITIONS TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 59 REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR THE TREATMENT OF ACUTE & CHRONIC WOUNDS
    • TABLE 60 REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 61 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 62 EUROPE: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 63 APAC: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.5 DENTAL
    • 7.5.1 RISING INCIDENCE OF ORAL DISORDERS TO DRIVE THE MARKET GROWTH
    • TABLE 64 REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 65 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 66 EUROPE: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 67 APAC: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.6 OCULAR DISORDERS
    • 7.6.1 RISING PRODUCT APPROVALS TO DRIVE MARKET GROWTH
    • TABLE 68 REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 69 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 70 EUROPE: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 71 APAC: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.7 OTHER APPLICATIONS
    • TABLE 72 REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 73 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 74 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 75 APAC: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018-2025 (USD MILLION)

8 REGENERATIVE MEDICINE MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 76 NUMBER OF PLAYERS IN THE REGENERATIVE MEDICINE MARKET, BY REGION, 2018 VS. 2019
    • TABLE 77 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY REGION (2019)
    • TABLE 78 REGENERATIVE MEDICINE MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 16 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
    • TABLE 79 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 80 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 81 NORTH AMERICA: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 82 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 Growing product pipeline to drive the market in the US
    • TABLE 83 PRODUCTS ANTICIPATED FOR APPROVALS IN THE US IN 2020
    • TABLE 84 PRODUCTS ANTICIPATED FOR FILINGS IN THE US IN 2020
    • TABLE 85 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 86 US: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 87 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Increasing investments in R&D to drive market growth
    • TABLE 88 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 89 CANADA: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 90 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 91 EUROPE: RESEARCH FUNDING OVERVIEW (2017)
    • TABLE 92 PRODUCTS ANTICIPATED FOR APPROVALS IN EUROPE IN 2020
    • TABLE 93 PRODUCTS ANTICIPATED FOR FILINGS IN EUROPE IN 2020
    • TABLE 94 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 96 EUROPE: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 97 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.3.1 UK
      • 8.3.1.1 Rising prevalence of chronic conditions to drive market growth in the UK
    • TABLE 98 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 99 UK: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 100 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.3.2 GERMANY
      • 8.3.2.1 Rising healthcare expenditure to propel market growth
    • TABLE 101 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 102 GERMANY: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 103 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Rising R&D expenditure, a major growth driver in France
    • TABLE 104 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 105 FRANCE: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 106 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.3.4 REST OF EUROPE
    • TABLE 107 ROE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 108 ROE: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 109 ROE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 17 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
    • TABLE 110 APAC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 111 APAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 112 APAC: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 113 APAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.4.1 JAPAN
      • 8.4.1.1 Comparatively lenient regulations and rising geriatric population to drive market growth
    • TABLE 114 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 115 JAPAN: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 116 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.4.2 CHINA
      • 8.4.2.1 Favorable investments and government support to drive market growth in China
    • TABLE 117 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 118 CHINA: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 119 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.4.3 AUSTRALIA
      • 8.4.3.1 Strong research base and availability of funds to drive market growth
    • TABLE 120 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 121 AUSTRALIA: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 122 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
    • 8.4.4 ROAPAC
    • TABLE 123 ROAPAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 124 ROAPAC: CELL THERAPIES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 125 ROAPAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)
  • 8.5 REST OF THE WORLD
    • TABLE 126 ROW: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 127 ROW: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2018-2025 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
    • FIGURE 18 KEY DEVELOPMENTS IN THE REGENERATIVE MEDICINE MARKET (JANUARY 2017 -AUGUST 2020)
  • 9.2 CELL THERAPY MARKET SHARE ANALYSIS
    • FIGURE 19 CELL THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
  • 9.3 GENE THERAPY MARKET SHARE ANALYSIS
    • FIGURE 20 GENE THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
  • 9.4 TISSUE ENGINEERING MARKET RANKING
    • FIGURE 21 TISSUE ENGINEERING MARKET RANKING, 2019
  • 9.5 COMPETITIVE SCENARIO
    • 9.5.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
    • TABLE 128 PRODUCT LAUNCHES & REGULATORY APPROVALS (JANUARY 2017-AUGUST 2020)
    • 9.5.2 COLLABORATIONS
    • TABLE 129 COLLABORATIONS (JANUARY 2017-AUGUST 2020)
    • 9.5.3 ACQUISITIONS
    • TABLE 130 ACQUISITIONS (JANUARY 2017-AUGUST 2020)
    • 9.5.4 EXPANSIONS
    • TABLE 131 EXPANSIONS (JANUARY 2017-AUGUST 2020)

10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES

  • 10.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
    • 10.1.1 VENDOR INCLUSION CRITERIA
    • 10.1.2 STARS
    • 10.1.3 EMERGING LEADERS
    • 10.1.4 PERVASIVE
    • 10.1.5 PARTICIPANTS
    • FIGURE 22 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
  • 10.2 COMPANY EVALUATION MATRIX FOR START-UPS (2019)
    • 10.2.1 PROGRESSIVE COMPANIES
    • 10.2.2 RESPONSIVE COMPANIES
    • 10.2.3 STARTING BLOCKS
    • 10.2.4 DYNAMIC COMPANIES
    • FIGURE 23 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019
  • 10.3 COMPANY PROFILES

(Business overview, Products offered, Recent developments, MNM view)**

    • 10.3.1 SMITH & NEPHEW PLC
    • FIGURE 24 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2019)
    • 10.3.2 VERICEL CORPORATION
    • FIGURE 25 VERICEL CORPORATION: COMPANY SNAPSHOT (2019)
    • 10.3.3 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    • FIGURE 26 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019)
    • 10.3.4 MIMEDX GROUP
    • FIGURE 27 MIMEDX GROUP: COMPANY SNAPSHOT (2019)
    • 10.3.5 NOVARTIS AG
    • FIGURE 28 NOVARTIS: COMPANY SNAPSHOT (2019)
    • 10.3.6 STRYKER CORPORATION
    • FIGURE 29 STRYKER CORPORATION: COMPANY SNAPSHOT (2019)
    • 10.3.7 ORGANOGENESIS INC.
    • FIGURE 30 ORGANOGENESIS: COMPANY SNAPSHOT (2019)
    • 10.3.8 MEDIPOST CO., LTD.
    • FIGURE 31 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2019)
    • 10.3.9 3M GROUP
    • FIGURE 32 3M GROUP: COMPANY SNAPSHOT (2019)
    • 10.3.10 MISONIX
    • FIGURE 33 MISONIX: COMPANY SNAPSHOT (2019)
    • 10.3.11 ZIMMER BIOMET
    • FIGURE 34 ZIMMER BIOMET: COMPANY SNAPSHOT (2019)
    • 10.3.12 MEDTRONIC PLC
    • FIGURE 35 MEDTRONIC PLC: COMPANY SNAPSHOT (2019)
    • 10.3.13 AMGEN, INC.
    • FIGURE 36 AMGEN, INC.: COMPANY SNAPSHOT (2019)
    • 10.3.14 ALLERGAN
    • FIGURE 37 ALLERGAN: COMPANY SNAPSHOT (2019)
    • 10.3.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • FIGURE 38 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2019)
    • 10.3.16 ORTHOCELL LTD.
    • 10.3.17 TEGO SCIENCE, INC.
    • 10.3.18 CORESTEM, INC.
    • 10.3.19 ANTEROGEN CO., LTD.
    • 10.3.20 BLUEBIRD BIO
    • 10.3.21 SPARK THERAPEUTICS
    • 10.3.22 KITE PHARMA
    • 10.3.23 APAC BIOTECH
    • 10.3.24 SHENZHEN SIBIONO GENETECH CO., LTD.
    • 10.3.25 ASPECT BIOSYSTEMS

*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 11.2 DISCUSSION GUIDE
  • 11.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.4 AVAILABLE CUSTOMIZATIONS
  • 11.5 RELATED REPORTS
  • 11.6 AUTHOR DETAILS